About Peptidings

Peptidings exists because the peptide research space deserved better than what was available. Every site we found was either shallow, promotional, or dishonest about the evidence. We decided to build the one we wanted to read.

This site publishes comprehensive, evidence-based research overviews on peptide compounds—written for researchers, clinicians, and informed readers who want to understand the science rather than be sold a conclusion. We cover mechanisms of action, clinical and preclinical evidence, safety profiles, regulatory status, and community-reported practices, and we are honest about the limits of the evidence at every step.

What We Publish

The core of Peptidings is a growing library of longform pillar articles—comprehensive research overviews covering individual peptide compounds in depth. These are not summaries scraped from other sources. Each article follows a rigorous editorial template: mechanism of action, key research areas, common claims versus current evidence, the human studies gap, safety and risks, regulatory status, dosing in published research, and dosing as reported in self-experimentation communities.

We also publish practical guides covering topics from reconstitution technique to reading a certificate of analysis, a glossary of peptide science terminology, and condition-specific landing pages that map compounds to the health topics readers are actually researching.

As of April 2026, the site includes over 110 compound articles across 19 research clusters, 30 guides, a 400-term glossary, and 12 condition pages—with more in active production.

Editorial Standards

Every compound article on Peptidings is assessed against a five-tier evidence framework that distinguishes FDA-approved drugs from clinical trial candidates, from compounds with limited pilot data, from preclinical-only research. We apply this framework consistently and display the evidence tier prominently because readers deserve to know—before they invest time in a 7,000-word article—how strong the human evidence actually is.

Our editorial rules are simple and non-negotiable:

Animal model results do not automatically transfer to humans. We say so every time.
A single positive study generates a hypothesis, not an established fact.
Where the evidence is thin, we say the evidence is thin. We do not fill gaps with optimism.
We cite primary sources—peer-reviewed studies, clinical trial registries, regulatory agency documents. Where we cite secondary sources, we say so explicitly.
Community-reported practices are documented as descriptive data, not endorsed as protocols.
WADA status and FDA regulatory category are documented for every compound, every time.

This honesty is not a marketing position. It is the editorial standard that every piece of content on this site is held to, and it is the reason we believe Peptidings is worth reading.

How Content Is Produced

Peptidings uses AI tools as part of its research and production workflow. Every piece of content published on this site is human-directed, human-reviewed, substantially human-written, and human-approved for scientific accuracy, editorial integrity, and safety before publication. Our full production process is described in the Our Process section below.

AI does not determine our editorial positions. It does not decide what evidence to include or exclude, how to assess the strength of a study, or what to conclude about a compound. Those decisions are made by Lawrence based on primary source evaluation and the evidence framework described above. AI is a production tool—the same way a calculator is a tool for an accountant or a search engine is a tool for a journalist. The editorial judgment is human.

We disclose this because transparency is a core value of this site, and because we believe readers deserve to know how the content they are reading was produced. If you have questions about our editorial process, reach out.

Editorial Independence

Peptidings maintains a strict separation between editorial content and advertising. Sponsorships, affiliate relationships, and advertising do not influence compound assessments, evidence tier assignments, safety discussions, or any editorial content on this site. A partnership does not buy a favorable mention, a softened risk assessment, or a higher evidence tier.

This is documented in detail on our Advertise page, including explicit commitments about what we will and will not do for advertising partners. We keep these commitments because our editorial credibility is the asset that makes everything else on this site worth building.

Who We Are

Peptidings was founded by Lawrence Winnerman—a product and program leader, content strategist, and lifelong science generalist who spent two decades building technology products and editorial systems before turning that toolkit toward peptide research.

Lawrence’s professional background is in technology and media, not medicine. He spent years at Microsoft as a program lead on the Online Store, managing complex product systems at scale. He has built content strategies, managed multimillion-dollar programs, and learned—through a career of shipping products under real constraints—that rigor is not the enemy of accessibility. You can be thorough and clear at the same time. Most people just choose not to be.

The origin of Peptidings was personal. Lawrence started researching peptides the way most people do: trying to separate real evidence from marketing noise for his own health decisions. What he found was a landscape of shallow vendor pages, recycled blog posts making identical unsupported claims, and forum threads where anecdotal experience was treated as clinical data. The sites that ranked highest on Google were often the least honest about what the science actually showed.

The gap was clear—and it was a content problem, not a science problem. The published research existed. Thousands of peer-reviewed studies on hundreds of peptide compounds sat in PubMed, most of them never translated into language a non-specialist could actually use. The issue was not a lack of evidence. It was a lack of anyone willing to read the evidence carefully, organize it honestly, and present it in a way that respected both the science and the reader.

That is what Peptidings was built to do. Lawrence brings a builder’s discipline to the work: systematic frameworks for evaluating evidence, structured templates that ensure every compound gets the same rigorous treatment, and an editorial voice—the Dutch Uncle—that tells the truth about what the data shows and what it does not, even when the truth is less exciting than the marketing.

He is not a physician or a research scientist, and Peptidings does not pretend otherwise. What he is: someone with the technical ability to build a production system that can process hundreds of primary sources per compound, the editorial judgment to distinguish strong evidence from weak evidence, and the stubborn conviction that readers deserve better than what the peptide internet currently offers. The medical and scientific claims on this site are sourced exclusively from peer-reviewed literature, regulatory documents, and clinical trial registries—not from personal opinions about what works.

Our Process

Every compound article on Peptidings goes through a structured production pipeline. It begins with a research dossier—a comprehensive review of the published literature on PubMed, clinical trial registries, and regulatory databases. That dossier becomes a content brief, written against a standardized editorial template covering mechanism of action, key research, claims versus evidence, the human evidence landscape, safety, regulatory status, and dosing. The brief is reviewed for accuracy, voice, and evidence discipline before it becomes a published article.

AI tools—specifically Anthropic’s Claude—assist in this production workflow: literature review, initial drafting, structural formatting, and quality assurance checks. Every editorial decision—what evidence to include, how to characterize a study’s strength, what verdict to assign, what safety risks to flag—is made by Lawrence based on primary source evaluation. AI is the research assistant. The editorial judgment is human. Every article is substantially written, reviewed, and approved by a human before publication.

This process is not fast. A single compound article typically requires reviewing 20–60 published studies and produces 6,000–9,000 words of finished content. We publish at this depth because the alternative—shallow overviews that skip the hard questions—is what every other peptide site already does. The world does not need another one of those.

Newsletter — The Peptidings newsletter on Substack. Weekly evidence digests, compound spotlights, and editorial deep-dives.

Contact — Reach the editorial team with corrections, questions, or press inquiries.

Advertise — Newsletter sponsorships, affiliate partnerships, and display advertising for brands that serve the peptide research community.

Disclaimer — What this site is, what it is not, and what it cannot be used for.

Evidence Levels Explained — How we assess and categorize the strength of peptide research evidence.